Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669802 | 1.00 | CYP1A2 (0.42) | CYP1A2PPARGPPARAPPARDGSK3A | |
| SCHEMBL292209 | 0.90 | CYP1A2 (0.41) | CYP1A2PPARGPPARAPPARDGSK3A | |
| SCHEMBL1071481 | 0.76 | CYP1A2 (0.38) | CYP1A2PPARGPPARAPPARDGSK3A | |
| SCHEMBL1071483 | 0.76 | CYP1A2 (0.38) | CYP1A2GSK3AMAPK10RIOK2CYP2A6 | |
| SCHEMBL6443298 | 0.74 | SLC1A3 (0.55) | CYP1A2PPARGCYP2A6NPC1RAB9A | |
| SCHEMBL18241077 | 0.71 | CYP1A2 (0.52) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL13034170 | 0.70 | CYP1A2 (0.53) | CYP1A2PPARGPPARAPPARDCYP2A6 | |
| SCHEMBL1694910 | 0.69 | SLC6A2 (0.45) | CYP1A2GSK3AMAPK10RIOK2CYP2A6 | |
| SCHEMBL6519798 | 0.69 | SLC1A3 (0.50) | CYP1A2NPC1RAB9ASLC1A3SLC1A2 | |
| SCHEMBL487508 | 0.69 | ALDH1A1 (0.61) | CYP1A2CYP2A6RAB9ASLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4419513-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| WO-2010010150-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2009080761-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| US-20090143432-A1 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009035652-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3] DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | CYP1A2 2071/4885PPARG 3291/4885PPARA 3930/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | CYP1A2 1153/4885PPARG 2167/4885PPARA 3345/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | CYP1A2 1836/4885PPARG 2986/4885PPARA 2680/4885 |
| US-20090143432-A1 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | COMT, DRD2, DRD3 | CYP1A2 54/4885PPARG 2282/4885PPARA 1693/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | CYP1A2 2071/4885PPARG 3291/4885PPARA 3930/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | CYP1A2 2929/4885PPARG 4442/4885PPARA 1736/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | CYP1A2 1940/4885PPARG 2704/4885PPARA 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.